These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
790 related items for PubMed ID: 8895750
1. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Klus GT, Nakamura J, Li JS, Ling YZ, Son C, Kemppainen JA, Wilson EM, Brodie AM. Cancer Res; 1996 Nov 01; 56(21):4956-64. PubMed ID: 8895750 [Abstract] [Full Text] [Related]
2. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. Nnane IP, Kato K, Liu Y, Lu Q, Wang X, Ling YZ, Brodie A. Cancer Res; 1998 Sep 01; 58(17):3826-32. PubMed ID: 9731491 [Abstract] [Full Text] [Related]
3. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM. Cancer Res; 2000 Dec 01; 60(23):6630-40. PubMed ID: 11118046 [Abstract] [Full Text] [Related]
4. Inhibition of androgen synthesis in human testicular and prostatic microsomes and in male rats by novel steroidal compounds. Nnane IP, Kato K, Liu Y, Long BJ, Lu Q, Wang X, Ling YZ, Brodie A. Endocrinology; 1999 Jun 01; 140(6):2891-7. PubMed ID: 10342882 [Abstract] [Full Text] [Related]
5. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line. Amaral C, Varela C, Correia-da-Silva G, Tavares da Silva E, Carvalho RA, Costa SC, Cunha SC, Fernandes JO, Teixeira N, Roleira FM. Biochimie; 2013 Nov 01; 95(11):2097-106. PubMed ID: 23933094 [Abstract] [Full Text] [Related]
6. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis. Nnane IP, Long BJ, Ling YZ, Grigoryev DN, Brodie AM. Br J Cancer; 2000 Jul 01; 83(1):74-82. PubMed ID: 10883671 [Abstract] [Full Text] [Related]
7. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, Brodie AM. J Med Chem; 2005 Apr 21; 48(8):2972-84. PubMed ID: 15828836 [Abstract] [Full Text] [Related]
8. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. Yamaoka M, Hara T, Hitaka T, Kaku T, Takeuchi T, Takahashi J, Asahi S, Miki H, Tasaka A, Kusaka M. J Steroid Biochem Mol Biol; 2012 Apr 21; 129(3-5):115-28. PubMed ID: 22249003 [Abstract] [Full Text] [Related]
12. Effects of new 17alpha-hydroxylase/C(17,20)-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Grigoryev DN, Long BJ, Nnane IP, Njar VC, Liu Y, Brodie AM. Br J Cancer; 1999 Oct 21; 81(4):622-30. PubMed ID: 10574247 [Abstract] [Full Text] [Related]
14. Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line. Guillemette C, Hum DW, Bélanger A. Endocrinology; 1996 Jul 21; 137(7):2872-9. PubMed ID: 8770908 [Abstract] [Full Text] [Related]
15. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. Zhu YS, Cai LQ, You X, Cordero JJ, Huang Y, Imperato-McGinley J. J Androl; 2003 Jul 21; 24(5):681-7. PubMed ID: 12954658 [Abstract] [Full Text] [Related]